Bydureon Bcise (Exenatide Microspheres) Patent Expiration, LOE Window & CMS Spending
Bydureon Bcise (Exenatide Microspheres) by AstraZeneca: FDA Orange Book core substance LOE 2026-04-04 (last listed 2031-04-04), 0 AB generics, $267.7M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AstraZeneca |
| FDA Application & Pathway | N209210 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2026-04-04 |
| Last Listed Patent or Exclusivity Date | 2031-04-04 |
| Orange Book Patents (*PED Extensions) | 14 patents (7 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $267.7M |
| 2024 Medicare Part D Spend | $215.4M |
| 2024 Medicaid Spend | $52.3M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.